Alnylam Pharmaceuticals
ALNY
#569
Rank
HK$278.53 B
Marketcap
HK$2,159
Share price
1.16%
Change (1 day)
52.72%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -HK$32.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -HK$32.02. In 2022 the company made an earnings per share (EPS) of -HK$72.38 a decrease over its 2021 EPS that were of -HK$56.10.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$32.20-55.52%
2022-HK$72.3829.03%
2021-HK$56.10-3.36%
2020-HK$58.05-8.48%
2019-HK$63.427.67%
2018-HK$58.9039.74%
2017-HK$42.1512.94%
2016-HK$37.3238.84%
2015-HK$26.88-32.88%
2014-HK$40.05259.44%
2013-HK$11.14-31.25%
2012-HK$16.2152.94%
2011-HK$10.6030.77%
2010-HK$8.10-8.77%
2009-HK$8.8878.13%
2008-HK$4.99-70.78%
2007-HK$17.0699.09%
2006-HK$8.57-43.88%
2005-HK$15.27-82.33%
2004-HK$86.43-59.23%
2003-HK$212.00

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-HK$13.25-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$291.09-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$61.01 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$2.10-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$13.17-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$29.14-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$24.78-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-HK$15.58-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel